Features and properties of amubarvimab/romlusevimab

Alternative names	Amubarvimab: BRII-196; romlusevimab: BRII-198
Class	Antivirals; monoclonal antibodies
Mechanism of action	Virus internalization inhibitors
Route of administration	Intravenous
Pharmacodynamics	Amubarvimab and romlusevimab bind to distinct epitopes of the SARS-CoV-2 spike protein; neutralization activity of the antibodies in combination appears to be retained against a number of SARS-CoV-2 variants of concern
Pharmacokinetics (amubarvimab and romlusevimab)	Median time to maximum serum concentration of 4.6–6.6 h and 4.7–6.8 h, respectively, with mean systemic serum clearance values of 72.2–84.7 and 63.9–59.4 mL/day, respectively Mean terminal half-life of 44.6–48.6 and 72.2–83.0 days, respectively
Most frequent treatment-emergent adverse events	Diarrhoea, nausea, vomiting, fatigue, fever, chills, COVID-19 pneumonia, bronchitis, infusion-related reactions, increased BP, myalgia, headache, insomnia, oropharyngeal pain, cough, difficulty breathing, runny nose and high BP
ATC codes
WHO ATC code	J05 (antivirals for systemic use)
EphMRA ATC code	J5 (antivirals for systemic use)

SARS-CoV-2 severe acute respiratory syndrome coronavirus